Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
Go back to Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 533.00 -13.12 (2.4%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $546.12 | 52 Week High | $134.71 | |||
| Open | $529.64 | 52 Week Low | $73.31 | |||
| Day High | $535.00 | P/E | N/A | |||
| Day Low | $520.20 | EPS | $-1.98 | |||
| Volume | 240,624 | |||||
